Publication | Closed Access

Treatment of childhood acute myelogenous leukemia with an intensive regimen (AML-87) that individualizes etoposide and cytarabine dosages: short- and long-term effects

Hematological MalignancyOncologyLong-term EffectsPediatric HematologyMixed-phenotype Acute LeukemiaHematologyPharmacologyPharmacotherapyMedicineCytarabine DosagesIntensive RegimenMyeloid Neoplasia